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CYSTIC fibrosis (CF) lung disease is characterized by
persistent  inflammation.  Antiinflammatory  drugs,
such as corticosteroids and ibuprofene, have proved
to slow the decline of pulmonary function although
their  use  is  limited  because  of  frequent  adverse
events. We hypothesized that colchicine could be an
alternative treatment because of its antiinflammatory
properties and upregulatory effect on cystic fibrosis
transmembrane regulator (CFTR) closely related pro-
teins. We herein present results obtained in an open
study of eight CF children treated with colchicine for
at  least  6  months.  Clinical  status  was  better  in  all
patients and respiratory  function tests significantly
improved in five. Median duration of antibiotherapy
decreased  significantly.  These  preliminary  results
support  our  hypothesis  of  a  beneficial  effect  of
colchicine in CF  patients  and stress the need for a
controlled therapeutic trial.
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Introduction
Lung  disease  in  cystic  fibrosis  (CF)  patients  is
characterized by persistent bacterial infection leading
to  chronic  bronchitis  and  bronchectiasis.1 Vigorous
antibiotherapy,  clearance  of  mucus  and  adequate
nutritional support have been the bases of conven-
tional therapy. Recently, attention has been focused
on the lung inflammation which not only damages the
parenchyma directly but  also impairs local defence
against  pathogens.2,3 Blunting  the  inflammatory
response  by  using  antiinflammatory  drugs  such  as
corticosteroids or ibuprofen has been proven to slow
the decline of pulmonary function, although the high
incidence  of  adverse  events  outweighs  beneficial
effect.4,5
Colchicine should be considered as an alternative
treatment because of its antiinflammatory properties
notably by interference with PNN margination, chem-
otaxis and phagocytosis.6 Interestingly, colchicine has
also been shown to upregulate the expression of the
multi-drug-resistance (MDR) gene.7This gene encodes
for the P-glycoprotein or P-gp which belongs to the
ATP binding cassette (ABC) protein family and shares
remarkable homology with cystic fibrosis transmem-
brane regulator (CFTR).8 In vitro experiments have
shown that closely related ABC proteins can comple-
ment each other.9 Taken together, these data led us to
propose that colchicine might induce complementa-
tion of CFTR by P-gp.
Recently, we reported improvement of lung func-
tion  in  a  CF  patient  after  antitumoral  therapy  and
suggested that this could be due to the complementa-
tion of CFTR.10 However the toxicity of these drugs
precludes their wide use in  CF patients. We herein
present preliminary  results  showing that colchicine
may exert a beneficial effect on CF clinical status.
Materials and methods
Patients
Eight patients with CF diagnosed according to con-
ventional criteria entered this open study conducted
from 1 March 1997 to 31 December 1997.12 All these
patients  had  end-stage  CF  lung  disease  or  chronic
airflow limitation unresponsive to conventional ther-
apy.  Colchicine  (Houd´ e,  Paris,  France)  was  admin-
istered orally  (1mg  daily),  during  at  least  6  moths
without other antiinflammatory treatment (inhaled or
oral  steroid  therapy,  nonsteroidal  antiinflammatory
drugs) or recombinant human DNase.
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3  months  during  the  duration  of  the  assay,  i.e.  at
least  6  months:  body  weight  (BW)  and  height
(expressed as standard deviation from  ideal  weight
and  height  for  age);  respiratory  function  tests
(forced  expiratory  volume– FEV1,  and  forced  vital
capacity–FVC); number of antibiotic courses in rela-
tion  to  respiratory  tract  infections.  Concomitant
therapies  and  adverse  clinical  events  were
documented.
Statistics
Results are presented as median (range) values. The
average values in the 6 months before the beginning
of  treatment  were  compared  with  their  post-treat-
ment average after completion of at least 6 months of
treatment. Statistical analysis was done using Wilcox-
on’s signed rank test. P value of less than 0.05 was
considered significant.
Results
Patient characteristics
Eight patients (six boys) were studied. The character-
istics  of  the  patients at  beginning  of  treatment are
shown in Table 1. Median age was 13.5 years (range
5–28 years). Six patients were D F508  homozygous.
Median FEV1 and FVC were respectively 54% (range
21–63%) and 62% (37–64%). Patient 7 was a 27-year-
old patient with secondary nephropathic amyloidosis.
The occurrence of renal failure justified the start of
colchicine therapy. Patient 8 was a 13-year-old girl on
the lung transplant waiting list because of a dramatic
decline of respiratory function and nutritional status
(Fig.  1).  Patient  2  and  patient  8  both  also  had
concomitant long-term azithromycin started 2 years
before.
Effect of colchicine on patient clinical status
Median duration of treatment was 7 months (range
6–12 months). No child had change in the baseline
treatment during the study period. For all the patients
there was a subjective improvement in clinical status.
Median  duration  of  antibiotherapy  significantly
decreased from 5 to 1.2 days per month (P < 0.05).
Median weight gain was + 0.25SD (P = 0.1).
The respiratory function tests could be performed in
seven  patients.  FEV1  substantially  improved  in  six
patients, rising from 54% (21–63%) predicted to 57%
(37–64%)  predicted  (P =  0.14).  In  contrast,  FVC
remained unchanged during the duration of colchicine
therapy. Patient 8, on the lung transplant waiting list,
had a marked improvement of FEV1 from 21% to 37%
predicted, and FVC from 32% to 44% which prompted
his removal from this list. Concomitantly, weight gain
(4kg) and reduced need for antibiotics (15 days during
the 6 months after beginning of treatment versus 30
days during the 6 months before) were observed. The
child had recovered good daily  activity.  It is worth
noting that there had been no concomitant change in
the usual treatment of this patient.
Adverse effects
The drug was well tolerated except in two patients
who  had  mild  diarrhoea.  However,  this  mild  side
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Table 1. Baseline characteristics of patients before colchicine treatment
Patient (No.) Age (years) BW* CF mutation FVC** FEV1** Lung colonization
1 10 –0.5 DF508/DF508 66% 54% P. aeruginosa
2 16 –1 DF508/DF508 65% 60% P. aeruginosa Staph. aureus B. Cepacia
3 14 –0.5 DF508/DF508 81% 78% Staph. aureus
4 5 –1.5 ? ND ND P. aeruginosa Staph. aureus
5 6 –2 DF508/DF508 66% 54% H. influenzae
6 13 0.5 DF508/DF508 90% 92% P. aeruginosa
7 28 –1 DF508/DF508 72% 61% P. aeruginosa
8 14 –2 DF508/? 32% 32% P. aeruginosa B. Cepacia
Median 13.5 –1 54 62
Range 5–28 –2–0.5 21–63 32–68
*Expressed as SD for theoretical weight for age;
**Expressed as percentages of theoretical value for age and sex.
FIG. 1. Evolution of FEV1 and FVC. *Wilcoxon’s signed rank
test.effect  did  not  lead  to  discontinuation  of  the
treatment.
Discussion
We report preliminary results showing that colchicine
treatment  in  CF  patients  is  associated  with  a  sig-
nificant  decrease of antibiotherapy,  and  a  potential
improvement of respiratory status. To our knowledge,
colchicine  has  not  yet  been  proposed  in  CF  but
interestingly, it has already been used for the treat-
ment  of  idiopathic  pulmonary  fibrosis12 and  IgE-
mediated asthma.13
The beneficial effect of colchicine may be due to
two different mechanisms: (i) colchicine has antiin-
flammatory properties due to interference with PNN
margination,  chemotaxis  and  phagocytosis14 and
inhibition of leukotriene synthesis.15 It also inhibits
fibroblast proliferation and total collagen synthesis;16
(ii)  colchicine  also  promotes  expression  of  ABC
proteins such as P-gp which shares great structural
homology with CFTR.7,8,17,18 Several recent data also
suggest  functional  homology.  CFTR  overexpression
leads to a multidrug-resistance phenotype similar to
P-gp.19 CFTR  exports  glutathione  and  glucuronate
anions  and  may  play  a  role  in  cell  detoxification
similar  to  MRP.20,21 As  closely  related ABC proteins
can  complement  each  other,  upregulation  of  P-gp
and/or  MRP  may  hence  lead  to  functional  com-
plementation of defective CFTR.9,10 This hypothesis
is also supported by the expression of MDR in nasal
epithelial  cells  of  a  CF  patient  treated  with  anti-
tumorous drugs but not in a control CF patient who
never had chemotherapy.10 This function of upregu-
lation of ABC proteins could be emphasized by the
adjunction  of  other ABC  protein  inducers  such  as
azithromycin.22 Interestingly, two patients were trea-
ted by both drugs and experienced an improvement
in  clinical  status.
In conclusion, colchicine should be considered in
the  treatment in  CF  patients, because  of  its  antiin-
flammatory  role  and  its  property  of  inducing ABC
proteins. Although preliminary, the potential impor-
tance of these results in this severe disease seems to
us to justify their early report and has formed the basis
of a controlled trial which is now being undertaken
by our group.
References
1. Koch  C,  Hoiby  N.  Pathogenesis of  cystic fibrosis.  Lancet 1993; 341:
1065–1069.
2. Khan TZ, Wagener  JS, Bost T,  et al. Early  pulmonary  inflammation  in
infants  with  cystic  fibrosis.  Am  J  Respir  Crit  Care  Med 1995;  151:
1075–1082.
3. Descamps-Latscha B, D¨ oring G, Galanaud P , Lenoir G, Navarro J, Schaffar
L. Inflammation in Cystic Fibrosis. Med Inflamm 1996; 5: 121–143.
4. Auerbach  HS, Williams  M,  Kirkpatrick  JA,  Cotten  HR. Alternate  day
prednisolone reduces the morbidity and improves pulmonary function
in cystic fibrosis. Lancet 1985; ii: 686–688.
5. Konstan  MW,  Byard  PJ,  Hoppel  CL,  Davis  PB.  Effect  of  high-dose
ibuprofen  in  patients  with  cystic  fibrosis.  N  Engl  J Med 1995; 331:
848–854.
6. Levy  M,  Spino  M,  Read  E.  Colchicine:  a  state  of  the  art  review.
Pharmacother 1991; 11(3): 196–211.
7. Ueda  K,  Pastan  I,  Gottesman  MM.  Isolation  and  sequence  of  the
promoter  region  of  the  human  multidrug-resistance  (P-glycoprotein)
gene. J Biol Chem 1987; 262: 17432–17436.
8. Higgins CF. ABC transporters: from microorganisms to man. Annu Rev
Biol 1992; 8: 67–113.
9. Tommasini R, Evers R, Vogt E, et al. The human multidrug  resistance-
associated protein functionally complements the yeast cadmium resist-
ance factor 1. Proc Natl Acad Sci USA 1996; 93: 6743–6748.
10. Lallemand  JY,  Stoven V, Annereau JP, Boucher J,  Blanquet S, Barthe J,
Lenoir G. Induction by antitumoral drugs of proteins that functionally
complement CFTR: a novel therapy for cystic fibrosis? Lancet 1997; 350:
711–712.
11. Stern RC. The diagnosis  of  cystic fibrosis.  N Engl  J Med 1997; 336:
487–491.
12. Douglas WW, Ryu JH, Swensen SJ, et al. Colchicine versus prednisone in
the treatment of idiopathic pulmonary fibrosis. Am J Resp Crit Care Med
1998; 158: 220–225.
13. Kelly SJ, Uri AJ, Freeland HS, et al. Effects of colchicine on IgE-mediated
early and late airway reactions. Chest 1995; 107: 985–991.
14. Dallaverde E, Fan PT, Chang YH. Mechanism of action of colchicine. V.
Neutrophil  adherence  and  phagocytosis  in  patients  with  acute  gout
treated with colchicine. J Pharmacol Exp Ther 1982; 223: 197–202.
15. Peters-Golden  M,  McNish  RW,  Davis  JA,  et  al.  Colchicine  inhibits
arachidonate release and 5-lipoxygenase action in alveolar macrophages.
Am J Physiol 1996; 271: 6 Pt 1, L1004–1013.
16. Entzian P, Schlaak M, Seitzer U, et al. Antiinflammatory and antifibrotic
properties of colchicine: implications for idiopathic pulmonary fibrosis.
Lung 1997; 175: 41–51.
17. Vollrath V, Wielandt AM, Acuna C, et al. Effect of colchicine and heat
shock on multidrug resistance gene and P-glycoprotein expression in rat
liver. J Hepatol 1994; 21: 754–763.
18. Eliseenkova AV, Kakpakova ES, Abdrjashitov RI, Stavrovskaya AA. Colchi-
cine-resistance  and  enhancment  of  P-glycoprotein  activity  after  co-
cultivation of drug-sensitive cells with multidrug resistant variants. Cell
Biol Int 1995; 19(2): 113–119.
19. Wei LY, Stutts MJ, Hoffman MM, Roepe PD. Overexpression of the CFTR
in NIH 3T3 cells lowers membrane potential and intracellular  pH and
confers  a  multidrug  resistance  phenotype.  Biophys  J 1995;  69:
883–895.
20. Lindsdell P , Hanrahan JW. Glutathione permeability of CFTR. Am J Cell
Physiol 1998; 275(44): C323–326.
21. Lindsdell P , Hanrahan JW. Adenosine triphosphate dependant assymetry
of  anion  permeation  in  cystic  fibrosis  transmembrane  conductance
regulator chloride channel. J Gen Physiol 1998; 111: 601–614.
22. Altschuler EL. Azithromycin, the multidrug-resistant protein, and cystic
fibrosis. Lancet 1998; 351: 1286.
ACKNOWLEDGEMENT. This work was supported by the association ‘ABCF
Prot´ eine’.
Received 17 November 1998;
accepted in revised form 18 December 1998
Colchicine in cystic fibrosis
Mediators of Inflammation · Vol 8 · 1999 15